Ranolazine — brands & medicines in Pakistan
Pakistan mein Ranolazine ke 1 brands available hain. Drug class: Anti-anginal / Late Sodium Channel Inhibitor. Neeche se koi bhi brand select karein aur uses, dosage, side effects aur price dekhein.
Quick Answer
Ranolazine is a anti-anginal / late sodium channel inhibitor used in Pakistan for Stable Angina (add-on therapy), Refractory angina when other anti-anginals are insufficient, Angina in patients with contraindications to beta-blockers or nitrates. Available as 1 brand. Prescription required. Always confirm dose with a doctor or pharmacist.
What is Ranolazine?
Ranolazine is a anti-anginal / late sodium channel inhibitor used in Pakistan for a range of medical conditions. Doctors and pharmacists in Pakistan recognize Ranolazine under multiple brand names — currently 1 listed on PakVita (1 tablet). The information below is a synthesis from DRAP-registered medicine entries, BNF, and WHO Essential Medicines references.
Common indications
- Stable Angina (add-on therapy)
- Refractory angina when other anti-anginals are insufficient
- Angina in patients with contraindications to beta-blockers or nitrates
Indication and dose vary by medical condition, age, weight, and other factors. Always confirm with a qualified doctor or pharmacist before starting.
Typical dosage
500mg twice daily, may increase to 1000mg twice daily as tolerated
This is a general adult guidance pattern based on the manufacturer's label for one of the Ranolazine brands listed below. Children, elderly patients, pregnant women, and people with kidney or liver impairment usually need different dosing — confirm with your doctor.
Side effects
Common (usually mild)
- Dizziness (Chakkar)
- Headache (Sar dard)
- Constipation (Qabz)
- Nausea (Matli)
Serious — stop and see a doctor
- QT prolongation — irregular heartbeat (Dil ki dhadkan ka irregular hona)
- Syncope (Behoshi)
- Severe renal impairment with prolonged use
Important warnings
- Do not use in cirrhosis (severe liver disease)
- Avoid in QT prolongation or with QT-prolonging drugs
- Do not crush extended-release tablet
- CYP3A4 inhibitors (ketoconazole, clarithromycin) significantly raise levels
Ranolazine brands in Pakistan (1)
Click any brand to see full uses, dosage, side effects, prices, and warnings.
Frequently asked questions
What is Ranolazine used for in Pakistan?
Ranolazine is commonly used for Stable Angina (add-on therapy), Refractory angina when other anti-anginals are insufficient, Angina in patients with contraindications to beta-blockers or nitrates. It belongs to the anti-anginal / late sodium channel inhibitor drug class.
What is the typical dosage of Ranolazine?
Typical adult dosing is described by manufacturers as: "500mg twice daily, may increase to 1000mg twice daily as tolerated". Always confirm dose, duration, and timing with a qualified doctor or pharmacist — dose depends on indication, weight, age, kidney/liver function, and other medications.
What are the common side effects of Ranolazine?
Common side effects include Dizziness (Chakkar), Headache (Sar dard), Constipation (Qabz), Nausea (Matli). Most are mild and resolve as the body adjusts. Stop the medicine and contact a doctor if side effects are severe, persistent, or include allergic symptoms (rash, swelling, breathing difficulty).
When should I stop Ranolazine and see a doctor?
Stop Ranolazine and seek urgent medical care if you experience: QT prolongation — irregular heartbeat (Dil ki dhadkan ka irregular hona); Syncope (Behoshi); Severe renal impairment with prolonged use. These are serious signs that need immediate attention.
Is Ranolazine available without a prescription in Pakistan?
Prescription required.
What brands of Ranolazine are available in Pakistan?
1 brand of Ranolazine is listed on PakVita: 1 tablet. Browse the brand list below and click any name for prices, dosage, and full information.
Sources
- DRAP Registered Drug Products Database — Drug Regulatory Authority of Pakistan
- British National Formulary (BNF) — BMJ Group & Pharmaceutical Press
- WHO Model List of Essential Medicines, 23rd ed. — World Health Organization